Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus nab-paclitaxel and gemcitabine in first-line CLDN18.2-positive metastatic pancreatic adenocarcinoma
2024-510985-17-00Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of zolbetuximab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Recommended phase 2 dose confirmation, Safety and tolerability and 1 more. Started Mar 2019; status: completed.
02
Drugs
zolbetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-510985-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510985-17-00.